*SB0139.1*
January 19, 2024
SENATE BILL No. 139
_____
DIGEST OF SB 139 (Updated January 17, 2024 12:11 pm - DI 104)
Citations Affected: IC 16-18; IC 16-46.
Synopsis: Psilocybin treatment program. Establishes the therapeutic
psilocybin research fund, administered by the Indiana department of
health (state department), to provide financial assistance to research
institutions in Indiana to study the use of psilocybin to treat mental
health and other medical conditions. Sets forth clinical study
requirements. Requires a research institution that receives a grant to
conduct a clinical study to prepare and submit a report to the interim
study committee on public health, behavioral health, and human
services, the state department, and the division of mental health and
addiction.
Effective: Upon passage.
Charbonneau, Johnson T
January 8, 2024, read first time and referred to Committee on Health and Provider
Services.
January 18, 2024, amended, reported favorably — Do Pass; reassigned to Committee on
Appropriations.
SB 139—LS 6465/DI 147 January 19, 2024
Second Regular Session of the 123rd General Assembly (2024)
PRINTING CODE. Amendments: Whenever an existing statute (or a section of the Indiana
Constitution) is being amended, the text of the existing provision will appear in this style type,
additions will appear in this style type, and deletions will appear in this style type.
Additions: Whenever a new statutory provision is being enacted (or a new constitutional
provision adopted), the text of the new provision will appear in this style type. Also, the
word NEW will appear in that style type in the introductory clause of each SECTION that adds
a new provision to the Indiana Code or the Indiana Constitution.
Conflict reconciliation: Text in a statute in this style type or this style type reconciles conflicts
between statutes enacted by the 2023 Regular Session of the General Assembly.
SENATE BILL No. 139
A BILL FOR AN ACT to amend the Indiana Code concerning
health.
Be it enacted by the General Assembly of the State of Indiana:
1 SECTION 1. IC 16-18-2-143, AS AMENDED BY P.L.1-2010,
2 SECTION 69, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
3 UPON PASSAGE]: Sec. 143. (a) "Fund", for purposes of IC 16-26-2,
4 has the meaning set forth in IC 16-26-2-2.
5 (b) "Fund", for purposes of IC 16-31-8.5, has the meaning set forth
6 in IC 16-31-8.5-2.
7 (c) "Fund", for purposes of IC 16-41-39.4, refers to the childhood
8 lead poisoning prevention fund established by IC 16-41-39.4-3.1.
9 (d) "Fund", for purposes of IC 16-41-39.8, refers to the lead trust
10 fund established by IC 16-41-39.8-7.
11 (e) "Fund", for purposes of IC 16-46-5, has the meaning set forth in
12 IC 16-46-5-3.
13 (f) "Fund", for purposes of IC 16-46-12, has the meaning set forth
14 in IC 16-46-12-1.
15 (g) "Fund", for purposes of IC 16-41-42.2, has the meaning set forth
16 in IC 16-41-42.2-2.
17 (h) "Fund", for purposes of IC 16-35-8, has the meaning set forth in
SB 139—LS 6465/DI 147 2
1 IC 16-35-8-2.
2 (i) "Fund", for purposes of IC 16-46-17.5, has the meaning set
3 forth in IC 16-46-17.5-1.
4 SECTION 2. IC 16-18-2-296.4 IS ADDED TO THE INDIANA
5 CODE AS A NEW SECTION TO READ AS FOLLOWS
6 [EFFECTIVE UPON PASSAGE]: Sec. 296.4. "Psilocybin", for
7 purposes of IC 16-46-17.5, has the meaning set forth in
8 IC 16-46-17.5-2.
9 SECTION 3. IC 16-46-17.5 IS ADDED TO THE INDIANA CODE
10 AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTIVE
11 UPON PASSAGE]:
12 Chapter 17.5. Therapeutic Psilocybin Research
13 Sec. 1. As used in this chapter, "fund" refers to the therapeutic
14 psilocybin research fund established by section 3 of this chapter.
15 Sec. 2. (a) As used in this chapter, "psilocybin" means a
16 naturally occurring psychedelic prodrug compound that is
17 produced by fungi, including members of the genus psilocybe.
18 (b) The term includes psilocin.
19 Sec. 2.5. As used in this chapter, "research institution" refers to
20 an organization that meets all of the following:
21 (1) Has an academic institution that operates an institutional
22 review board (IRB) that oversees research.
23 (2) Publishes the results of previous clinical trials in peer
24 reviewed publications.
25 (3) Has access to a clinical research center and the center's
26 resources, including research dedicated medical staff.
27 Sec. 3. The therapeutic psilocybin research fund is established
28 for the purpose of providing financial assistance to research
29 institutions in Indiana to study, in accordance with the
30 requirements established in section 6 of this chapter, the use of
31 psilocybin to treat mental health and other medical conditions.
32 Sec. 4. (a) The fund shall be administered by the state
33 department.
34 (b) The expenses of administering the fund shall be paid from
35 money in the fund.
36 Sec. 5. (a) The fund consists of the following:
37 (1) Appropriations from the general assembly.
38 (2) Donations to the fund.
39 (3) Gifts to the fund.
40 (b) The treasurer of state shall invest the money in the fund not
41 currently needed to meet the obligations of the fund in the same
42 manner as other public money may be invested. Interest that
SB 139—LS 6465/DI 147 3
1 accrues from these investments shall be deposited in the fund.
2 (c) Money in the fund at the end of a state fiscal year does not
3 revert to the state general fund.
4 Sec. 6. (a) A research institution in Indiana may apply to the
5 state department to receive financial assistance from the fund to
6 conduct one (1) or more clinical studies to evaluate the efficacy of
7 psilocybin as an alternative treatment for mental health and other
8 medical conditions, including the following:
9 (1) Posttraumatic stress disorder, with a focus on treating the
10 disorder in combat veterans and first responders.
11 (2) Anxiety.
12 (3) Depression.
13 (4) Bipolar disorder.
14 (5) Chronic pain.
15 (6) Migraines.
16 (b) In conducting a clinical study under this section, a research
17 institution that receives a grant under this chapter shall do the
18 following:
19 (1) Include veterans and first responders in the study sample.
20 (2) Evaluate and determine whether psilocybin is an effective
21 treatment for mental health and other medical conditions
22 described in subsection (a).
23 (3) Compare the efficacy of psilocybin as a treatment for
24 mental health and other medical conditions described in
25 subsection (a) with the efficacy of other current treatment
26 options for mental health and other medical conditions
27 described in subsection (a).
28 (4) Before entering the study, require each participant to
29 undergo a mental health evaluation.
30 Sec. 7. After a research institution that receives a grant under
31 this chapter completes and finalizes a study under this chapter, a
32 research institution shall prepare and submit a report
33 summarizing the results of the study and any recommendations for
34 legislation to the following:
35 (1) The interim study committee on public health, behavioral
36 health, and human services established by IC 2-5-1.3-4 in an
37 electronic format under IC 5-14-6.
38 (2) The state department.
39 (3) The division of mental health and addiction.
40 Sec. 8. Not later than July 1, 2024, the state department shall
41 establish a process to administer the fund and process applications
42 under this chapter.
SB 139—LS 6465/DI 147 4
1 SECTION 4. An emergency is declared for this act.
SB 139—LS 6465/DI 147 5
COMMITTEE REPORT
Madam President: The Senate Committee on Health and Provider
Services, to which was referred Senate Bill No. 139, has had the same
under consideration and begs leave to report the same back to the
Senate with the recommendation that said bill be AMENDED as
follows:
Page 2, between lines 18 and 19, begin a new paragraph and insert:
"Sec. 2.5. As used in this chapter, "research institution" refers
to an organization that meets all of the following:
(1) Has an academic institution that operates an institutional
review board (IRB) that oversees research.
(2) Publishes the results of previous clinical trials in peer
reviewed publications.
(3) Has access to a clinical research center and the center's
resources, including research dedicated medical staff.".
Page 3, line 9, after "institution" insert "that receives a grant under
this chapter".
Page 3, line 21, after "institution" insert "that receives a grant
under this chapter".
and when so amended that said bill do pass and be reassigned to the
Senate Committee on Appropriations.
(Reference is to SB 139 as introduced.)
CHARBONNEAU, Chairperson
Committee Vote: Yeas 11, Nays 0.
SB 139—LS 6465/DI 147